Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315703 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 393
- Enrollment target
NCT02315703 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 393 participants.
The verdict
NCT02315703, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 393 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) components and to compare envelope binding antibody responses between the different vaccine regimens.
Interventions
- DRUG Placebo
- BIOLOGICAL Ad26.Mos.HIV
- BIOLOGICAL MVA-Mosaic
- BIOLOGICAL gp140 DP Low-dose
- BIOLOGICAL gp140 DP High-dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2014-12-22 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315703
The ClinicalTrials.gov registry entry for NCT02315703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02315703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02315703 about?
NCT02315703 is a clinical study titled "Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention". The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) components and to co...
What is the current status of trial NCT02315703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 393 participants. The study started on 2014-12-22. Estimated completion is 2022-03-28.
What interventions are being tested in trial NCT02315703?
The interventions under investigation include: Placebo (DRUG), Ad26.Mos.HIV (BIOLOGICAL), MVA-Mosaic (BIOLOGICAL), gp140 DP Low-dose (BIOLOGICAL), gp140 DP High-dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT02315703?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.